首页> 美国卫生研究院文献>BMC Pediatrics >Early high flow nasal cannula therapy in bronchiolitis a prospective randomised control trial (protocol): A Paediatric Acute Respiratory Intervention Study (PARIS)
【2h】

Early high flow nasal cannula therapy in bronchiolitis a prospective randomised control trial (protocol): A Paediatric Acute Respiratory Intervention Study (PARIS)

机译:细支气管炎的早期高流量鼻导管治疗一项前瞻性随机对照试验(方案):一项儿童急性呼吸道干预研究(PARIS)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundBronchiolitis imposes the largest health care burden on non-elective paediatric hospital admissions worldwide, with up to 15 % of cases requiring admission to intensive care. A number of previous studies have failed to show benefit of pharmaceutical treatment in respect to length of stay, reduction in PICU admission rates or intubation frequency. The early use of non-invasive respiratory support devices in less intensive scenarios to facilitate earlier respiratory support may have an impact on outcome by avoiding progression of the disease process. High Flow Nasal Cannula (HFNC) therapy has emerged as a new method to provide humidified air flow to deliver a non-invasive form of positive pressure support with titratable oxygen fraction. There is a lack of high-grade evidence on use of HFNC therapy in bronchiolitis.
机译:背景毛细支气管炎给全世界非选择性儿科医院住院带来了最大的医疗保健负担,多达15%的病例需要接受重症监护。许多先前的研究未能显示药物治疗在住院时间,降低PICU入院率或插管频率方面的益处。在强度较低的情况下尽早使用无创呼吸支持设备以促进早期呼吸支持可能会通过避免疾病进程的进展而对结果产生影响。高流量鼻插管(HFNC)治疗已成为一种新方法,可提供加湿的气流以提供无创形式的可滴定氧气含量的正压支持。缺乏关于在细支气管炎中使用HFNC治疗的高级证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号